Skip to main content Skip to search Skip to main navigation

EU GMP Guide: Chapter 4, Annex 11 and New Annex 22

The EC has published the long-awaited revised and new documents of the EU GMP Guide for consultation: Chapter 4 Documentation, Annex 11 Computerised Systems and the new Annex 22 Artificial Intelligence. Stakeholder consultations are open until 7 October on the EC website.

Revision of Chapter 4 – Documentation

The updated Chapter 4 emphasises the critical role of documentation in GMP and supports the use of digital, hybrid, and emerging technologies. Risk-based data governance is now a core element to ensure document accuracy, integrity, availability, and legibility across all formats. It also clarifies requirements for managing electronic records, signatures, and data integrity, aligning with the ongoing revision of Annex 11.

Revision of Annex 11 – Computerised Systems

The updated Annex 11 reinforces lifecycle management of computerised systems, requiring comprehensive application of Quality Risk Management. It strengthens requirements for system specifications, supplier oversight, data integrity, audit trails, electronic signatures, and security.

New Annex 22 – Artificial Intelligence

Annex 22 sets out requirements for the use of AI and machine learning in the manufacture of active substances and medicinal products. It covers model selection, training, validation, and performance monitoring. Key areas include intended use, data quality, performance metrics, change control, and human oversight.


Source:

EC: Public Health/Consultations/ Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EU: Analysis Supporting the Proposed Biotech Act

EU: Analysis Supporting the Proposed Biotech Act

The European Commission has published the analysis underpinning the proposed Biotech Act. The initiative aims to strengthen Europe’s biotechnology and biomanufacturing sectors and to accelerate the development, production and market uptake of biotechnology-based innovations.
Read more
EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.
Read more
What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

The EMA has published the final version of the scientific guideline „Development and manufacture of synthetic peptides“.
Read more
EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

The European Commission has published a new communication on reinforcing global health resilience, with a strong focus on resilient pharmaceutical supply chains, expanded manufacturing capacity, and security of supply for critical health products.
Read more
Previous
Next